Novartis Adds To NASH Pipeline By Licensing Pliant’s Integrin Inhibitor
Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.
You may also be interested in...
Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.